In the quest for effective treatments for scleroderma, Koçak (2025) explores the potential of JAK inhibitors, a type of medication that targets a specific cell signaling pathway involved in autoimmune responses. These inhibitors have shown promise in animal models, reducing fibrosis in the skin and lungs, which are common issues in scleroderma. However, clinical studies in humans are limited.
Initial findings suggest that JAK inhibitors could be more effective in patients who have not received prior treatments for scleroderma, as indicated by a significant reduction in skin scores after starting treatment. While these results are encouraging, Koçak emphasizes the need for more clinical trials to fully assess the safety and efficacy of JAK inhibitors for scleroderma patients, with a focus on improving patient well-being and quality of life.
More Info 
Add to Calendar 